Syros Pharmaceuticals Inc SYRS released initial data from its ongoing SELECT-AML-1 Phase 2 trial of tamibarotene in combination with venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression. In December 2022, Syros reported data…
#syrs #selectaml1phase2 #myeloid #aml #rara #syros #selectaml1 #crcri #median #select
Continue reading...